<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Adding Erbitux to First Line Chemotherapy Helps Advanced Colorectal Cancer Patients with Wild Type KRAS</title>
	<atom:link href="http://fightcolorectalcancer.org/research_news/2010/06/adding_erbitux_to_first_line_chemotherapy_helps_advanced_colorectal_cancer_patients_with_wild_type_kras/feed" rel="self" type="application/rss+xml" />
	<link>http://fightcolorectalcancer.org/research_news/2010/06/adding_erbitux_to_first_line_chemotherapy_helps_advanced_colorectal_cancer_patients_with_wild_type_kras</link>
	<description>We envision victory over colorectal cancer</description>
	<lastBuildDate>Wed, 23 May 2012 21:37:02 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
	<item>
		<title>By: Kate Murphy</title>
		<link>http://fightcolorectalcancer.org/research_news/2010/06/adding_erbitux_to_first_line_chemotherapy_helps_advanced_colorectal_cancer_patients_with_wild_type_kras/comment-page-1#comment-8789</link>
		<dc:creator>Kate Murphy</dc:creator>
		<pubDate>Sat, 27 Nov 2010 15:46:39 +0000</pubDate>
		<guid isPermaLink="false">http://fightcolorectalcancer.org/?p=8768#comment-8789</guid>
		<description>What is important in elderly patients is not their age, but if they have other serious medical problems -- what doctors call &quot;medically fit.&quot; 

Erbitux (cetuximab) is as effective in older patients who are medically fit as it is in younger ones.

If it is combined with irinotecan (FOLFIRI), older patients may have more side effects.  Experience has found older patients may need a lower dose of irinotecan to reduce risk of side effects.</description>
		<content:encoded><![CDATA[<p>What is important in elderly patients is not their age, but if they have other serious medical problems &#8212; what doctors call &#8220;medically fit.&#8221; </p>
<p>Erbitux (cetuximab) is as effective in older patients who are medically fit as it is in younger ones.</p>
<p>If it is combined with irinotecan (FOLFIRI), older patients may have more side effects.  Experience has found older patients may need a lower dose of irinotecan to reduce risk of side effects.</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Nancy</title>
		<link>http://fightcolorectalcancer.org/research_news/2010/06/adding_erbitux_to_first_line_chemotherapy_helps_advanced_colorectal_cancer_patients_with_wild_type_kras/comment-page-1#comment-8783</link>
		<dc:creator>Nancy</dc:creator>
		<pubDate>Sat, 27 Nov 2010 13:43:27 +0000</pubDate>
		<guid isPermaLink="false">http://fightcolorectalcancer.org/?p=8768#comment-8783</guid>
		<description>Do you have any information on age of the patient at the time of the initiation of chemo and how that factor influences the outcomes?</description>
		<content:encoded><![CDATA[<p>Do you have any information on age of the patient at the time of the initiation of chemo and how that factor influences the outcomes?</p>
]]></content:encoded>
	</item>
</channel>
</rss>

